A unilateral directive bypassing institutional drug review protocols
On October 28, 2026, Health and Human Services Secretary Robert F. Kennedy Jr. announced that the federal government would permit widespread patient access to six unapproved peptide compounds popularized across social media platforms. The decision bypasses bedrock FDA requirements, including double-blind placebo testing, evaluation of carcinogenic risks, and screening for teratogenic reproductive hazards.
Framing the decision under the doctrine of "enforcement discretion", the department signaled it will tacitly permit compounding pharmacies to formulate and distribute these unproven injectables.
















